Search results
Results From The WOW.Com Content Network
By 2015 the annual price of Kalydeco had been increased to more than $300,000 per patient. According to an article published in the Milwaukee Journal Sentinel Vertex executives "grossed more than $100 million by cashing in stocks and stock options" and at "one point, the value of company's stock increased more $6 billion in a single day."
At recent prices, you can buy Vertex stock for about 35.2 times trailing free cash flow. This is a high multiple, but the business is growing fast enough to justify the valuation. Trailing free ...
The S&P 500 is a stock market index maintained by S&P Dow Jones Indices. It comprises 503 common stocks which are issued by 500 large-cap companies traded on American stock exchanges (including the 30 companies that compose the Dow Jones Industrial Average). The index includes about 80 percent of the American equity market by capitalization.
Despite Vertex's strong gains over the past few years, this can still be an excellent stock to buy right now. Trading at a price/earnings-to-growth ratio, or PEG, of just 0.6, Vertex may even turn ...
Joshua S. Boger (born April 12, 1951) is an organic chemist and the founder of Vertex Pharmaceuticals Incorporated. He is considered a pioneer in the field of structure-based rational drug design. Drugs developed include amprenavir, an HIV protease inhibitor; telaprevir, a protease inhibitor for treatment of hepatitis C; and Kalydeco, for the ...
For premium support please call: 800-290-4726 more ways to reach us
Vertex was founded in 1978 by Ray Westphal. Jeff Westphal, Stevie Westphal Thompson and Amanda Westphal Radcliffe purchased interest in the company from their father in 2000. [1] On July 29, 2020, the company went public on the Nasdaq stock exchange.
Vertex Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs -2013 investment focused on key development programs in cystic fibrosis ...